You are here

  • Home
  • Archive
  • Volume 77, Issue 3
  • Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Nakaoka Y, Isobe M, Takei S, et al
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
Annals of the Rheumatic Diseases 2018;77:348-354.